When should lesion NAAT be collected for genital herpes?

Unroof a fresh vesicle or swab the moist base of an ulcer per local microbiology instructions; PCR/NAAT sensitivity drops as lesions crust—chart time from symptom onset and avoid substituting random asymptomatic swabs for diagnosis.

Why is routine IgM serology discouraged?

IgM assays lack type specificity and may be falsely positive during unrelated recurrences; management pivots on type-specific IgG with confirmatory testing when low-positive, or lesion NAAT for active lesions.

How soon should episodic oral antivirals start?

Best benefit arrives when therapy begins within about 24 hours of lesion onset or during prodrome; stock a prescription or pack for patient-initiated treatment where protocol allows.

Who merits suppressive therapy beyond comfort?

Frequent recurrences, high transmission anxiety in discordant couples (especially with HSV-2), and some pregnancy plans—final regimens and trimester nuances are prescriber-led.

What HIV linkage applies after genital HSV diagnosis?

CDC stresses testing people with genital herpes for HIV because HSV-2 ulcers facilitate HIV acquisition; document offer/result alongside other STI screens such as gonorrhoea testing when risk fits.

When should pregnant patients trigger urgent obstetric review?

First-episode genital HSV in late pregnancy, prodromal symptoms near labour, or uncertain lesion history with labour onset—local obstetric teams decide acyclovir suppression and delivery mode.

Which neonatal findings warrant emergency activation?

Vesicles on skin, eye or mouth in an infant at risk, seizures, lethargy, fever without focus, or maternal new genital HSV around delivery—escalate to emergency neonatal services per protocol.

How long should hygiene and lesion precautions continue?

While moist lesions ooze, emphasize hand hygiene, linen handling, and avoid autoinoculation or cross-contact; shedding can occur without lesions so counselling must stay accurate but non-shaming.

Genital Herpes: Diagnosis, Treatment & Prevention | NurseOnShift

🦠 Infectious Disease · STI / mucocutaneous ulcer

Genital Herpes: Diagnosis, Treatment & Prevention

Shift-oriented reference for genital HSV: HSV-1 vs HSV-2 epidemiology, when lesion NAAT changes management, how acyclovir-class antivirals are deployed for episodic and suppressive therapy, HIV co-testing, obstetric escalation around labour, and neonatal herpes watch-points.

⏱️23 min read

📅Updated May 3, 2026

✓Medically Reviewed

✍️

Written by

Sid Ahmed Abdala Balal

RGN

🩺

Reviewed by

Dr. Harriet Blundell

✨

Featured snippet

Genital herpes is a chronic HSV-1/HSV-2 infection causing recurrent painful genital ulcers or vesicles, often with unrecognised asymptomatic shedding. Nurses anchor care on lesion NAAT, timely oral acyclovir-class antivirals for first and recurrent episodes, HIV testing, and urgent obstetric pathways when pregnancy intersects a new outbreak—because neonatal HSV, meningoencephalitis, and disseminated HSV are rare but collapse quickly without escalation.

🔑Key Takeaways

Lesion NAAT/PCR while vesicles are fresh confirms HSV-1 vs HSV-2 and distinguishes mimics—waiting for crusting erodes sensitivity; tie specimen time to symptom clock.
First clinical episodes warrant systemic acyclovir, valacyclovir, or famciclovir; episodic therapy works best when patients initiate within roughly 24 hours of prodrome, so advance prescriptions matter.
Suppressive regimens cut recurrence frequency and can lower HSV-2 transmission in serodiscordant couples—reassess yearly because natural history often mellows.
Guideline-consistent care includes offering HIV testing with genital herpes diagnosis because HSV-2 ulcers potentiate HIV acquisition.
Late-pregnancy first episodes, disseminated visceral disease, and any concerning neonatal skin findings are emergency-tier triggers—not routine clinic deferrals.

⚡ Quick Facts

📊

Global HSV-2 burden

~13% of WHO adults 15–49 with HSV-2

📍

U.S. HSV-2 serology

~12% of US 14–49 with HSV-2 per CDC

⚠️

HIV synergy

HSV-2 raises HIV acquisition ~3× per WHO

⏱️

Antiviral window

Start episodic Rx at prodrome or <48h for best effect.

💡 Clinical Pearl

Low-positive HSV-2 IgG needs confirmatory testing—blindly labelling serology can devastate relationships. Pair serologic uncertainty with repeat/confirmatory pathways and, when lesions exist, prioritise NAAT over guesswork; never order non-specific IgM “herpes panels.”

📋 Contents

❓

What is Genital Herpes?

Genital herpes is chronic herpes simplex virus (HSV) infection of the genital and perianal skin and mucosa. Both HSV-1 and HSV-2 cause genital herpes; historically HSV-2 dominated recurrences, but HSV-1 from oral–genital contact now accounts for a large share of first-episode genital HSV, especially among young women and many MSM cohorts. After primary infection the virus establishes latency in regional sensory ganglia, then reactivates to produce episodic mucocutaneous shedding with or without visible vesicles or ulcers.

Viral replication triggers brisk innate responses, accounting for pain, oedema, and dysuria during outbreaks. Because subclinical shedding is common—particularly with HSV-2—concordance between symptoms and infectiousness is unreliable. Nursing assessment therefore emphasises lesion evolution, hydration status, pregnancy gestation, immunocompromise markers, and mental-health context rather than anchoring safety solely on “no visible sores.”

🚨

High-stakes clusters (pregnancy, newborn, immunocompromise)

🚨Do not miss

Primary or non-primary first-episode genital HSV in late pregnancy—obstetric teams weigh acyclovir suppression and delivery mode because neonatal herpes risk rises with acquisition close to labour.
Fever plus altered mental status, headache, or meningismus in a patient with known or suspected HSV—consider HSV meningitis or encephalitis pathways and urgent physician activation per local neurology guidance.
Pregnant patients with fever and fulminant hepatitis without classic skin lesions—guidelines highlight disseminated HSV as a rare catastrophic mimic requiring empiric IV acyclovir pending PCR confirmation.
Neonates with vesicles, lethargy, seizures, temperature instability, or breastfeeding refusal when maternal HSV status is uncertain—escalate immediately; time-critical IV therapy dramatically alters outcomes.

These scenarios override routine sexual-health clinic pacing; document time-critical discussions and transport decisions verbatim.

🔍

Symptoms

First-episode genital HSV classically produces grouped painful vesicles on an erythematous base that ulcerate, crust, and heal over 2–3 weeks, often with regional lymphadenopathy, fever, headache, and myalgia. Recurrent episodes are shorter, localised, and preceded by prodromal tingling or burning in many patients. A substantial proportion remain asymptomatic or misattribute minor irritation to friction or hygiene products.

Atypical or subtle cues

Unilateral labial swelling or fissures without tense vesicles—still warrant NAAT when sexual risk factors align; see the overview of labial swelling for wider differentials.
Recurrent dysuria out of proportion to dipstick findings—differentiate from infection by history of episodic triggers; when fever emerges use the dysuria with fever guide for pyelonephritis cues versus mucosal ulceration.
Pruritic or vesicular genital rashes after new partners—chart morphology photos (with consent) and flag concurrent gonorrhoea screening when discharge coexists; compare morphology against genital rash patterns.

🧬

Causes and Risk Factors

Transmission requires mucocutaneous contact with infectious secretions or lesions, yet asymptomatic shedding means infectiousness persists between visible outbreaks. HSV-1 acquisition frequently follows receptive oral sex from partners with unsuspected cold sores (oral herpes); HSV-2 remains predominantly sexually transmitted, with higher efficiency male-to-female than female-to-male.

Risk amplifiers

HIV: genital ulcers breach mucosal integrity—people living with undiagnosed HIV/AIDS benefit from integrated testing and PrEP counselling when indications exist.
Immunosuppression, eczema involving adjacent skin, or breaks in barrier from shaving traumata increase potential for wide local spread—maintain strict hand hygiene and lesion coverage.

🔬

How is it Diagnosed?

Clinical assessment

Record lesion age (fresh vesicle versus crusted ulcer), prior similar episodes, partner symptoms, trauma mimics, and medication allergies before antiviral orders. Map dermatosis beyond hair-bearing skin—perianal and sacral presentations are easily under-documented.

Laboratory investigations

HSV NAAT/PCR from ulcer base or vesicle fluid is first-line when lesions are present; sensitivity falls quickly as epithelium heals—coordinate specimen collection logistics early in clinic flow.
When only culture-capable labs exist, viral culture remains acceptable yet less sensitive, especially for recurrences.
Type-specific IgG serology assists when recurrent atypical symptoms occur with negative lesion PCR; interpret low-positive HSV-2 ELISA results cautiously and repeat or confirm per guideline algorithms. IgM panels are misleading and should not be ordered.
Offer HIV testing alongside initial STI evaluation; pair with other site-specific screens per exposure anatomy.

Imaging

Not routine; reserve for disseminated or CNS concerns under specialist direction.

🧩

Differential Diagnoses

Alternative	Bedside differentiators
Syphilitic chancre / non-HSV ulcerative STI mix	Painless vs exquisitely tender, adenopathy pattern, concurrent urethral discharge—keep expanded STI panel per sexual health service.
Bacterial vaginosis or irritant dermatitis	Fishy discharge versus grouped vesicles; symptoms improve when triggers removed—still perform lesion NAAT if vesicles ever appeared.
Fixed drug eruption, eczema, psoriasis plaque	Chronic morphology, lack of viral prodrome—biopsy rarely needed acutely.
Scabies burrows or folliculitis	Nocturnal pruritus, linear burrows, positive household contacts.
Urinary tract infection	Suprapubic symptoms with pyuria and typical urine culture—lack recurrent clustered vesicles.
Cellulitis	Progressive warmth and unilateral lymphangitis beyond an HSV plaque—requires antibiotics, not antivirals alone.

On a small screen, swipe or scroll sideways to see the full table.

💊

Treatment Options

Systemic acyclovir, valacyclovir, and famciclovir shorten first-episode severity, accelerate healing of recurrences, and suppress symptomatic relapses (see CDC’s detailed genital herpes management recommendations). Topical antivirals add negligible value. Dosing, renal adjustment, and duration stay prescriber-led; nursing responsibilities centre on medication access, adherence coaching, and monitoring for neurotoxicity cues in renal impairment.

First-line management

Treat every clinically diagnosed first episode—oral acyclovir, valacyclovir, or famciclovir courses typically span 7–10 days with extension if ulcer healing lags.
Provide patient-held episodic scripts with explicit “start at prodrome” instructions; align tablet counts with travel and weekend risk.
Suppressive regimens benefit frequent recurrences, high psychosocial burden, or discordant couples aiming to lower HSV-2 transmission—document shared decision-making annually.

Inpatient or IV pathways

Disseminated infection, hepatitis, pneumonitis, pregnancy with severe mucosal disease, or CNS involvement require IV acyclovir until clinical improvement, followed by oral completion—observe intravenous line integrity and hourly urine output targets per protocol.

Special populations

Pregnancy: obstetric physicians select third-trimester suppression doses and intrapartum plans—nurses surface timely lesion checks on admission for labour-and-delivery triage.
Breastfeeding: cover active breast lesions; avoid infant contact with open sores on the chest—coordinate lactation support without implying blanket cessation when lesions are distant.

📋

Clinical Practice Considerations

Sexual-health workflows hinge on non-judgemental history-taking, rapid NAAT logistics, and safety netting when patients leave before results return.

Monitoring: review lesion pain scores and ability to void each shift when patients are admitted for dehydration or pregnancy complications; chart oral intake and antiemetics.
Infection control: lesions are contact risks for autoinoculation and neonates—reinforce isolation precautions only when institutional policy designates moist extensive lesions or coexisting immunosuppression; routine ward care rarely needs airborne measures.
Partners: document that index-case diagnosis triggers guideline-based partner notification pathways handled by sexual health services.

Clinical decision flow (shift-ready)

Grouped painful genital vesicles → send HSV NAAT, add HIV serology where not recent, offer immediate oral antiviral if prescriber available.
Pregnant with new genital ulceration → escalate to obstetric senior same shift regardless of gestational triage category.
Negative NAAT but recurrent compatible symptoms → arrange type-specific IgG with confirmatory testing per lab scientist advice.
Recurrent outbreaks >6/year or severe psychosocial impact → refer for suppressive regimen review within 2 weeks.

Bedside monitoring checklist

Pain score, oral hydration, urinary retention cues.
Maternal temperature and fetal heart rate when pregnant.
Neurosurgical watch in patients reporting thunderclap headache or photophobia with active genital HSV.

⚠️

Possible Complications

Secondary bacterial skin infection, urinary retention from severe oedema, extragenital autoinoculation (digits, eyes—urgent ophthalmology if ocular pain).
HSV meningitis, neonatal HSV sepsis, disseminated visceral disease—each requires tiered escalation beyond oral therapy.
Chronic neuropathic pain syndromes after severe sacral outbreaks—multidisciplinary follow-up.

🛡️

Prevention

Condoms partially reduce HSV-2 transmission but fail where lesions sit on uncovered skin—pair barrier methods with abstinence during prodrome. Suppressive therapy with acyclovir-class drugs lowers symptomatic shedding frequency among discordant couples but never eliminates risk. Clinician-facing counselling cites WHO estimates—globally hundreds of millions carry HSV-2—to normalise testing without minimising disclosure obligations.

📈

Prognosis and Outlook

Genital HSV is lifelong; outbreak frequency often declines after the first year, especially for HSV-1 genital infections. Antivirals control symptoms yet do not eradicate latent virus. Psychosocial adjustment frequently dictates quality of life as much as virology—signpost peer-support frameworks used in your institution.

👩‍⚕️

In Clinical Practice…

Documentation & communication

Chart lesion distribution on anatomical diagrams, prior antiviral trials, allergy status, and pregnancy gestation. Avoid stigmatising language; use neutral phrasing such as “HSV serostatus discordant relationship” in handovers.

Medication teaching

Clarify that missing the 24–48 hour window still warrants starting therapy—delayed treatment may still shorten duration—and emphasise hydration with oral acyclovir-class drugs to protect renal function.

Equity & safeguarding

Youth, intimate partner violence survivors, and migrants may fear confidentiality breaches—offer chaperones and interpreter access per policy.

🚨

When to Seek Emergency Care

🚨Escalate urgently when

Signs of CNS involvement, refractory vomiting with encephalopathy, or seizure activity.
Hemodynamic instability, hypoxia, or disseminated pustules in pregnancy—consider empiric IV acyclovir per protocol while awaiting PCR.
Neonates with vesicles, fever, poor feeding, or seizures—activate emergency paediatric services.

📚

NCLEX practice questions

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of lesion NAAT timing, HIV/STI linkage, pregnancy neonatal risk and antiviral safety—mirroring the Clinical Judgment Measurement Model emphasis on prioritisation and safe action.

Unfolding case (Questions 1–3): Ms. R., 26, presents to urgent care with painful grouped vesicles on the labia for 14 h—first recognised outbreak. She is afebrile today and denies urinary retention; vitals stable. She is not pregnant on urine screening.

Question 1 · Type 6 — Case study · Layer 5 (Take actions) · Type 1 — MCQ · Family A (Priority — FIRST)

After screening immediate safety concerns, what should the nurse do FIRST?

Defer swabbing until lesions fully crust to “confirm” HSV. Obtain lesion-directed HSV NAAT per protocol (fresh vesicle/base swab), document symptom onset time, and notify the clinician for antiviral consideration. Order HSV IgM serology as the sole diagnostic test. Start empiric topical steroid cream without lesions assessment.

Question 2 · Type 6 — Case study · Layer 2 (Analyze cues) · Type 2 — SATA · Family C

Which contexts signal complicated genital HSV or need escalation beyond routine episodic counselling alone (follow local pathways)? Select all that apply.

Febrile systemic illness with disseminated-appearing mucocutaneous involvement. Significant immunocompromise (e.g., advanced untreated HIV risk context). Third-trimester first-episode genital HSV or labour prodrome uncertainty. Mild itching without lesions in a patient requesting printed clinic hours. Severe sacral pain with difficulty voiding suggesting urinary retention risk. Stable immunocompetent patient requesting suppressive therapy refill with unchanged pattern.

Question 3 · Type 6 — Case study · Layer 6 (Evaluate outcomes) · Type 2 — SATA · Family E (Deterioration cues)

Neonate born to mother with untreated active genital lesions — nursery update: At 72 h of life the infant develops clustered vesicles on the scalp, refuses feeds, temperature 38.4 °C, and has episodes of stiffening witnessed by parents.

Which findings should prompt immediate escalation for suspected neonatal HSV evaluation per protocol? Select all that apply.

Vesicular skin lesions in an at-risk neonate. Fever ≥38 °C in this clinical context. Parent-reported seizure-like stiffening episodes. Poor feeding / lethargy trajectory. Routine cord stump care teaching completed without abnormal findings. Strong cry with vigorous feeding and normal glucose surveillance.

Question 4 · Type 1 — MCQ · Family F (Multi-patient triage)

Four sexual-health clinic requests arrive simultaneously. Which patient should the nurse assess FIRST?

Patient A — requests repeat suppressive valacyclovir refill; mild recurrence, afebrile. Patient B — 16-day-old infant with vesicles and fever; maternal genital HSV history unclear. Patient C — stable partner notification paperwork question. Patient D — asymptomatic STI screen appointment running 10 minutes late.

Question 5 · Type 4 — Ordered response · Family H

Place nursing actions for an adult with acute symptomatic genital HSV during initial evaluation (1 = first).

Use privacy and standard precautions; perform focused lesion assessment and onset timing.
Collect lesion NAAT specimen per microbiology instructions before lesions dry when feasible.
Notify clinician for antiviral orders and pregnancy/STI screening pathways as indicated.
Offer guideline-consistent HIV testing linkage counselling alongside other indicated screens.
Teach lesion hygiene, abstaining during moist lesions, and when to seek urgent care.

Question 6 · Type 8 — Matrix · Family G (Matrix / matching)

Choose the best initial nursing pathway emphasis for each scenario.

Scenario	Education / routine outpatient counselling	Urgent clinician pathway — pregnancy neonatal risk & IV therapy consideration	Emergency pathway — neonatal sepsis / CNS trajectory
Immunocompetent adult mild recurrence requesting episodic antiviral counselling
39 weeks, first painful genital ulcers today — uncertain prodrome versus labour onset
Neonate under 6 weeks with vesicles + fever + poor feeding
New diagnosis discussing why HIV testing is offered